CLDN6 and breast carcinoma: The results showed that breast cancer patients with high beclin1 expression had significantly longer OS than patients with low beclin1 expression, and patients with high ERβ, CLDN6 and beclin1 expression levels showed longer DFS than the respective low expression groups (Fig. 7d).